GPP
AVEO

Great Point Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Great Point Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-232,500
Closed -$4.25M – 47
2014
Q2 		$4.25M Sell
232,500
-54,148
-19% -$704K 1.89% 18
2014
Q1 		$4.29M Sell
286,648
-13,352
-4% -$240K 2.24% 17
2013
Q4 		$5.49M Buy
+300,000
New +$6.01M 3.88% 11

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Great Point Partners's AVEO Position: Q3 2014 in Review

Great Point Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2014, closing a stake of 232,500 shares — an estimated $4.25M sold.

Great Point Partners first reported a position in AVEO in Q4 2013 and held it in 3 quarters. The position peaked at $5.49M in Q4 2013. 55 funds tracked by Wall St. Rank hold AVEO as of Q3 2014.

  • Great Point Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Great Point Partners sold 232,500 AVEO Pharmaceuticals, Inc. shares in Q3 2014, an estimated $4.25M.
  • Great Point Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 3 quarters.
  • Great Point Partners's AVEO Pharmaceuticals, Inc. position peaked at $5.49M in Q4 2013.
  • 55 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2014.

Based on Great Point Partners's 13F filing for Q3 2014, filed 14 Nov 2014.